Frontiers in Oncology : Impact Factor & More
eISSN: 2234-943XpISSN: 2234-943X
Open AccessShare this on:
Key Metrics
CiteScore 
4.5
Eigenfactor
0.01 - 0.05
Impact Factor
< 5
Scite Index
0.89 5-Year SI
SJR
Q3Oncology
SNIP
1.19
Recommended pre-submission checks
Powered by 
Run standard language and technical checks to improve your manuscript – before you submit
Technical Compliance
Ensure manuscript complies with standard submission guidelines.
Language Quality
Improve clarity, grammar, and academic writing style.
A comprehensive report covering all these checks awaits you.
Topics Covered on Frontiers in Oncology
Frontiers in Oncology Journal Specifications
Indexed in the following public directories
Web of Science 
DOAJ 
SJR
| Overview | |
| Publisher | FRONTIERS MEDIA SA |
| Language | English |
| Frequency | Continuous publication |
| Article Processing Charges | USD 2950 |
| Publication Time | 14 |
| Editorial Review Process | Anonymous peer review |
| General Details | |
| Language | English |
| Frequency | Continuous publication |
| Publication Start Year | 2011 |
| Publisher URL | Visit website |
| Website URL | Visit website |
| Publication Details | |
| Editorial Review Detail | |
| Information for authors | |
| Author instructions | Visit website |
| Copyright Details | Visit website |
| Deposit Policy | Sherpa/Romeo |
| License type | CC BY |
| OA statement | Visit website |
View less
Planning to publish in Frontiers in Oncology ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Recently Published Papers in Frontiers in Oncology
B-cells in breast cancer: current insights and challenges
- 7 Aug 2026
- Frontiers in Oncology
Time to adjuvant chemotherapy after cytoreductive surgery and survival outcomes in epithelial ovarian cancer: a retrospective cohort study
- 7 Aug 2026
- Frontiers in Oncology
Immune profiling by bulk RNA-seq and multiplex immunofluorescence imaging across multiple cancer types
- 6 Aug 2026
- Frontiers in Oncology
Dual relevance of EIF2S1 in acute myeloid leukemia: linking poor prognosis to immune-metabolic states and leukemic cell fitness
- 5 Aug 2026
- Frontiers in Oncology
Gastric inflammatory myofibroblastic tumor in adults: a case report and literature review
- 29 Jul 2026
- Frontiers in Oncology
Multimodal AI fusion: integrating MRI with PET/CT, histopathology, and liquid biopsy for bone tumor diagnosis
- 27 Jul 2026
- Frontiers in Oncology
B-cells in breast cancer: current insights and challenges
- 7 Aug 2026
- Frontiers in Oncology
Time to adjuvant chemotherapy after cytoreductive surgery and survival outcomes in epithelial ovarian cancer: a retrospective cohort study
- 7 Aug 2026
- Frontiers in Oncology
Immune profiling by bulk RNA-seq and multiplex immunofluorescence imaging across multiple cancer types
- 6 Aug 2026
- Frontiers in Oncology
Dual relevance of EIF2S1 in acute myeloid leukemia: linking poor prognosis to immune-metabolic states and leukemic cell fitness
- 5 Aug 2026
- Frontiers in Oncology
Gastric inflammatory myofibroblastic tumor in adults: a case report and literature review
- 29 Jul 2026
- Frontiers in Oncology
Multimodal AI fusion: integrating MRI with PET/CT, histopathology, and liquid biopsy for bone tumor diagnosis
- 27 Jul 2026
- Frontiers in Oncology
FAQs on Frontiers in Oncology
How long has Frontiers in Oncology been actively publishing? 
What is the publishing frequency of Frontiers in Oncology?
How many articles did Frontiers in Oncology publish last year?
What is the eISSN & pISSN for Frontiers in Oncology?
What is Citescore for Frontiers in Oncology?
What is SNIP score for Frontiers in Oncology?
What is the SJR for Frontiers in Oncology?
Who is the publisher of Frontiers in Oncology?
